Mike, a scientist at Insmed, a Boulder, Colorado-based biotechnology company wants Washington to act now to allow access to safe, affordable follow-on biologics, or biogeneric medicines to treat diseases like cancer, MS, anemia, Lou Gehrig's disease or kidney failure.

Help Mike by telling your story about why Congress needs to act in the interest of patients, savings and competition.

While an estimated $20 billion worth of biologic drugs are expected to come off patent by 2015, no approval pathway currently exists at the Food and Drug Administration (FDA) to make follow-on biologics available to patients. Without this important pathway biotech companies will continue to have a monopoly and competition will not exist in the market. Without competition access to these critical medicines will remain expensive and will continue to drive up the overall healthcare expenditures in the US.